Internal Medicine, Hematology & Oncology · Reno, NV
NPI
1356430227
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
6130 Plumas St
Reno, NV, 89519
Phone (775) 329-0222
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.6M
123,943 services
Medicare patients, 2024
721
Average age 75
Drug cost, 2024
$4.2M
1,416 prescriptions
Company payments, 2025
$549
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Aaron T Bowman was code J9263 (injection, oxaliplatin, 0.5 mg), 11,400 times for 14 patients. In total Aaron T Bowman billed 123,943 services in 138 codes, and Medicare paid $2.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-08-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 11,400 | 14 | $0.06 | $644 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 11,000 | 24 | $44.77 | $492K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 10,800 | 16 | $39.52 | $427K |
| J0897 Injection, denosumab, 1 mg | Office | 5,040 | 19 | $20.62 | $104K |
| J0894 Injection, decitabine, 1 mg | Office | 3,400 | 12 | $1.24 | $4,226 |
| J0185 Injection, aprepitant, 1 mg | Office | 3,380 | 12 | $1.36 | $4,587 |
| J9267 Injection, paclitaxel, 1 mg | Office | 2,202 | 13 | $0.08 | $173 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,025 | 90 | $0.09 | $181 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,650 | 70 | $0.70 | $1,158 |
| Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 1,420 | 11 | $16.03 | $23K |
| 99214 Office E&M - Established | Office | 882 | 404 | $95.62 | $84K |
| 85025 Blood Count | Office | 706 | 355 | $7.59 | $5,361 |
| 36415 Venipuncture Blood Collection | Office | 597 | 327 | $8.62 | $5,148 |
| 96375 Injection Administration | Office | 547 | 105 | $11.83 | $6,472 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 516 | 20 | $0.07 | $37.88 |
By year: 2022 $2.3M for 114,127 services; 2023 $1.2M for 41,879 services; 2024 $2.6M for 123,943 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 706 | 355 | $7.59 | $5,361 |
| 36415 Venipuncture Blood Collection | 597 | 327 | $8.62 | $5,148 |
| 80053 Clinical Chemistry | 391 | 246 | $10.31 | $4,031 |
| 83615 Clinical Chemistry | 86 | 71 | $5.87 | $504 |
| 83735 Clinical Chemistry | 51 | 30 | $6.57 | $335 |
| 84443 Clinical Chemistry | 46 | 33 | $16.46 | $757 |
| 82728 Clinical Chemistry | 43 | 39 | $13.36 | $574 |
| 83550 Clinical Chemistry | 42 | 38 | $8.57 | $360 |
| 82607 Clinical Chemistry | 28 | 27 | $14.78 | $414 |
| 84100 Clinical Chemistry | 28 | 18 | $4.65 | $130 |
Medicare prescription drug claims, 2024
In 2024, the drug Aaron T Bowman prescribed most often to Medicare patients was Anastrozole, with 94 prescriptions and refills. In total Aaron T Bowman wrote 1,416 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 94 | 216 | 27 | $1,641 |
| Acyclovir Generic | 75 | 139 | 23 | $1,362 |
| Allopurinol Generic | 54 | 74 | Under 11 | $436 |
| Potassium Chloride Generic | 48 | 64 | 14 | $467 |
| Hydroxyurea Generic | 48 | 98 | 14 | $1,017 |
| Letrozole Generic | 46 | 82 | Under 11 | $711 |
| Gabapentin Generic | 40 | 60 | 13 | $314 |
| Eliquis Apixaban | 38 | 54 | Under 11 | $30K |
| Diphenhydramine Hcl Generic | 35 | 35 | Under 11 | $55.61 |
| Dexamethasone Generic | 32 | 46 | Under 11 | $563 |
| Imbruvica Ibrutinib | 32 | 34 | Under 11 | $464K |
| Brukinsa Zanubrutinib | 29 | 29 | Under 11 | $253K |
| Venclexta Venetoclax | 27 | 27 | Under 11 | $160K |
| Levothyroxine Sodium Generic | 25 | 40 | Under 11 | $218 |
| Tamoxifen Citrate Generic | 24 | 44 | Under 11 | $593 |
Brand drugs: 414 claims; generic drugs: 1,002 claims; opioid claims: 51.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Aaron T Bowman $549 ($549 in general payments such as food, travel and fees) from 17 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $98.87.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 3 | $98.87 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $55.58 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $43.25 |
| Pfizer Inc. PFE | 2 | $40.69 |
| SpringWorks Therapeutics, Inc. | 1 | $31.52 |
| Array Biopharma Inc PFE | 1 | $30.17 |
| Janssen Biotech, Inc. JNJ | 1 | $30.14 |
| Astellas Pharma US Inc 4503.T | 1 | $29.92 |
| Adc Therapeutics America, Inc. | 1 | $28.12 |
| Gilead Sciences, Inc. GILD | 1 | $27.44 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.